Substantial progress in the treatment of atherosclerotic complications – in particular in secondary prevention – has led to a significant reduction of recurrent cardiovascular events. This has been through the use of pharmacological strategies including lipid-lowering drugs such as statins, beta-blockers, angiotensin-converting ensyme inhibitors and angiotensin receptor blockers, along with the introduction of early percutaneous coronary intervention in acute coronary syndrome with consecutive application of dual antiplatelet therapy.

Related Articles


Atherosclerotic CVD Risk and Advanced Lipid Testing

Charles Amir German, Michael D Shapiro,


Citation: European Cardiology Review 2020;15:e56.

A Multicentre, Open-Label, Randomised Controlled Clinical Trial to Assess…

Morihiro Matsuda, Koji Hasegawa,


Citation: European Cardiology Review 2020;15:e47.

Statins and Insulin Resistance

GM Sanvee, M Panajatovic, J Bouitbir,

Citation: European Cardiology Review 2020;15:e44.

Role of PGC-1-alpha-associated Mitochondrial Biogenesis in Statin-induced…

M Panajatovic, F Singh, U Duthaler,

Citation: European Cardiology Review 2020;15:e35.